Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ali McBride

Showing results (41-50 of 145) with videos related to

Pageof 15
Sort By:
Pharmacoeconomics|September 18, 2016
Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical ReviewMahdi Gharaibeh, J Lyle Bootman, Ali McBride, et al.
Clinical Case Reports|September 25, 2015
Plerixafor as a salvage mobilization strategy for haploidentical peripheral blood allogeneic stem cell transplantationMichelle Nadeau, Laeth George, Andrew M Yeager, et al.
Expert Opinion on Drug Safety|January 15, 2021
Immune checkpoint inhibitors-associated risk of immune-related hypothyroidism in older patients with advanced melanoma: a real-world analysis of US SEER-Medicare dataAbdulaali R Almutairi, Brian L Erstad, Ali McBride, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|January 13, 2023
The economic value of knowing BRCA status: universal BRCA testing for breast cancer preventionMok Oh, Ali McBride, Sandipan Bhattacharjee, et al.
Future Oncology (London, England)|February 10, 2018
Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetronJeffrey Vacirca, Dennis Caruana, George Calcanes, et al.
Future Oncology (London, England)|July 9, 2021
Same-day versus next-day pegfilgrastim or pegfilgrastim-cbqv in patients with lymphoma receiving CHOP-like chemotherapyAli McBride, Neda Alrawashdh, Trace Bartels, et al.
Journal of Medical Economics|April 24, 2020
Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastimAli McBride, Weijia Wang, Kim Campbell, et al.
Journal of Managed Care & Specialty Pharmacy|April 30, 2021
Economic and clinical outcomes of pegfilgrastim via prefilled syringe vs on-body injector: a real-world data analysisAli McBride, Kim Campbell, Edward Li, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|January 24, 2023
The economic value of knowing BRCA status: <i>BRCA</i> testing for optimizing treatment in recurrent epithelial ovarian cancerMok Oh, Ali McBride, Sandipan Bhattacharjee, et al.
Annals of Hematology|January 14, 2016
Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic reviewScott C Howard, Steven Trifilio, Tara K Gregory, et al.
Pageof 15

Showing results (41-50 of 145) with videos related to

Sort By:
Pageof 15
Pharmacoeconomics|September 18, 2016
Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical ReviewMahdi Gharaibeh, J Lyle Bootman, Ali McBride, et al.
Clinical Case Reports|September 25, 2015
Plerixafor as a salvage mobilization strategy for haploidentical peripheral blood allogeneic stem cell transplantationMichelle Nadeau, Laeth George, Andrew M Yeager, et al.
Expert Opinion on Drug Safety|January 15, 2021
Immune checkpoint inhibitors-associated risk of immune-related hypothyroidism in older patients with advanced melanoma: a real-world analysis of US SEER-Medicare dataAbdulaali R Almutairi, Brian L Erstad, Ali McBride, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|January 13, 2023
The economic value of knowing BRCA status: universal BRCA testing for breast cancer preventionMok Oh, Ali McBride, Sandipan Bhattacharjee, et al.
Future Oncology (London, England)|February 10, 2018
Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetronJeffrey Vacirca, Dennis Caruana, George Calcanes, et al.
Future Oncology (London, England)|July 9, 2021
Same-day versus next-day pegfilgrastim or pegfilgrastim-cbqv in patients with lymphoma receiving CHOP-like chemotherapyAli McBride, Neda Alrawashdh, Trace Bartels, et al.
Journal of Medical Economics|April 24, 2020
Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastimAli McBride, Weijia Wang, Kim Campbell, et al.
Journal of Managed Care & Specialty Pharmacy|April 30, 2021
Economic and clinical outcomes of pegfilgrastim via prefilled syringe vs on-body injector: a real-world data analysisAli McBride, Kim Campbell, Edward Li, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|January 24, 2023
The economic value of knowing BRCA status: <i>BRCA</i> testing for optimizing treatment in recurrent epithelial ovarian cancerMok Oh, Ali McBride, Sandipan Bhattacharjee, et al.
Annals of Hematology|January 14, 2016
Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic reviewScott C Howard, Steven Trifilio, Tara K Gregory, et al.
Pageof 15